29 Jun 2018 07:00
AMPHION INNOVATIONS PLC
("Amphion" or "the Company")
Appointment of a New Director
London and New York, 29 June 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, today announces the appointment of Mr Philip Tansey as Non-executive director to the Company, effective immediately.
Philip Tansey is a qualified chartered accountant (ICAEW) and holds an honours degree in Biochemistry from Manchester University. He has over 25 years' experience, primarily in financial services, having started his career at Salomon Brothers. Until January 2017, he acted as Chief Financial Officer to the AIM listed company Panmure Gordon & Co. plc and prior to joining them in May 2011 he worked as a Managing Director for BGC Partners Inc. the NASDAQ listed inter-dealer broker.
Save as disclosed below, there are no further details required to be disclosed pursuant to schedule 2(g) of the AIM rules.
Philip Tansey (age 59) is, or has been in the previous five years, a director or partner, of the following companies:
Current appointments | Past appointments |
Baby Break and Toddler Break Limited | Durlacher Research Limited |
Tansey Associates Limited | Life Capital Limited |
To Health Limited | Panmure General Partner Limited |
| Panmure Gordon & Co. Limited |
| Panmure Gordon (Broking) Limited |
| Panmure Gordon (UK) Limited |
| Panmure Gordon Securities Limited |
| Primextend Limited |
| Rotherfield Nominees Limited |
| United Energy Limited |
| United Energy Properties Limited |
| Web-Angel Limited |
| Web-Angel Services Limited |
Mr Tansey was a director of Alfresco Leisure Publications Plc ("Alfresco") and its subsidiaries, Premier Guides Limited ("Premier Guides") and Telfo Limited ("Telfo"), all of which were placed into administration in 1992. Alfresco Leisure Publications and Premier Guides were dissolved on 16 November 1999 and Telfo was dissolved on 7 December 1993. The administrators of Premier Guides showed a deficiency of £0.6 million (excluding amounts owed to Alfresco) as regards to unsecured creditors. The administrators of Telfo showed a deficiency to creditors of £0.7 million.
Mr Tansey currently holds no beneficial interest in the Company.
For further information please contact:
Amphion Innovations | Tel: +1 (212) 210 6224 | ||||
Charlie Morgan |
| ||||
|
| ||||
Panmure Gordon (UK) Limited (Nominated Adviser and Corporate Broker) | Tel: +44 (0)20 7886 2500 | ||||
Freddy Crossley / Emma Earl (Corporate Finance) |
| ||||
Charlie Leigh-Pemberton (Corporate Broking) |
| ||||
|
| ||||
Northland Capital Partners Limited (Joint Corporate Broker) | Tel: +44 (0)20 3861 6625 | ||||
David Hignell (Corporate Finance) |
| ||||
John Howes (Corporate Broking) |
| ||||
|
| ||||
Walbrook PR | Tel: +44 (0)20 7933 8780 or | ||||
Paul McManus / Anna Dunphy | amphion@walbrookpr.com | ||||
|
| ||||
About Amphion Innovations plc - www.amphionplc.com
Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.